Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.
Abstract | BACKGROUND: OBJECTIVE: DESIGN: 12-month randomized, double-blind, placebo-controlled trial. SETTING: PATIENTS: INTERVENTIONS: MEASUREMENTS: The primary outcome was bone mineral density (BMD) measured by dual x-ray absorptiometry before transplantation and 3, 6, and 12 months later. Secondary outcomes included bone turnover markers that were measured before transplantation and 1, 3, 6, 9, and 12 months later. RESULTS: There were statistically significant interactions between treatment effects and time for BMD measurements at the lumbar spine (P = 0.002), femoral neck (P = 0.001), and total hip (P < 0.001). Differences in acute bone loss 3 months after transplantation favored zoledronic acid over placebo. Differences between groups in percentage change from baseline adjusted for baseline weight and serum parathyroid hormone (PTH) level were 4.0% (95% CI, 1.1% to 7.0%) for the lumbar spine, 4.7% (CI, 1.9% to 7.6%) for the femoral neck, and 3.8% (CI, 1.7% to 6.0%) for the total hip. At 12 months after transplantation, the difference in percentage change from baseline between the 2 groups adjusted for baseline weight and serum PTH level was 1.1% (CI, -2.1% to 4.4%) for the lumbar spine, 2.7% (CI, 0.0% to 5.4%) for the femoral neck, and 2.4% (CI, 0.1% to 4.7%) for the total hip. Treatment with zoledronic acid induced temporary secondary hyperparathyroidism and postinfusion hypocalcemia statistically significantly more often than did placebo. LIMITATIONS: The trial was not powered to assess fractures, and 10 of 62 (16%) patients were not included in adjusted analyses because of missing weight or serum PTH measurements. CONCLUSION:
|
Authors | Bronwyn A L Crawford, Cherie Kam, Julie Pavlovic, Karen Byth, David J Handelsman, Peter W Angus, Geoffrey W McCaughan |
Journal | Annals of internal medicine
(Ann Intern Med)
Vol. 144
Issue 4
Pg. 239-48
(Feb 21 2006)
ISSN: 1539-3704 [Electronic] United States |
PMID | 16490909
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Bone Density Conservation Agents
- Diphosphonates
- Hydroxycholecalciferols
- Imidazoles
- Parathyroid Hormone
- Zoledronic Acid
|
Topics |
- Bone Density
(drug effects)
- Bone Density Conservation Agents
(adverse effects, therapeutic use)
- Chronic Disease
- Diphosphonates
(adverse effects, therapeutic use)
- Double-Blind Method
- Follow-Up Studies
- Humans
- Hydroxycholecalciferols
(blood)
- Hyperparathyroidism, Secondary
(chemically induced)
- Hypocalcemia
(chemically induced)
- Imidazoles
(adverse effects, therapeutic use)
- Infusions, Intravenous
- Liver Failure
(complications, surgery)
- Liver Transplantation
(adverse effects)
- Osteoporosis
(etiology, prevention & control)
- Parathyroid Hormone
(blood)
- Zoledronic Acid
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|